Mirvetuximab soravtansine
Elahere (mirvetuximab soravtansine) is an antibody drug conjugate pharmaceutical. Mirvetuximab soravtansine was first approved as Elahere on 2022-11-14. It is used to treat fallopian tube neoplasms, ovarian epithelial carcinoma, and peritoneal neoplasms in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Elahere
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| elahere | Biologic Licensing Application | 2024-10-24 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| fallopian tube neoplasms | — | D005185 | — |
| ovarian epithelial carcinoma | — | D000077216 | — |
| peritoneal neoplasms | — | D010534 | — |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
mirvetuximab soravtansine, Elahere, ImmunoGen, Inc. | |||
| 2029-11-14 | Orphan excl. | ||
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
23 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 5 | 7 | 5 | — | — | 15 |
| Fallopian tube neoplasms | D005185 | — | — | 4 | 4 | 6 | — | — | 13 |
| Peritoneal neoplasms | D010534 | — | — | 1 | 5 | 4 | — | — | 9 |
| Ovarian epithelial carcinoma | D000077216 | — | — | 3 | 4 | 4 | — | — | 9 |
| Hypersensitivity | D006967 | HP_0012393 | T78.40 | — | 2 | 1 | — | — | 3 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Recurrence | D012008 | — | — | 2 | 2 | — | — | — | 4 |
| Endometrial neoplasms | D016889 | EFO_0004230 | — | — | 3 | — | — | — | 3 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 2 | 1 | — | — | — | 3 |
| Triple negative breast neoplasms | D064726 | — | — | 2 | 1 | — | — | — | 3 |
| Serous cystadenocarcinoma | D018284 | — | — | 1 | 1 | — | — | — | 2 |
| Neoplasms | D009369 | — | C80 | 2 | 1 | — | — | — | 2 |
| Fallopian tube diseases | D005184 | EFO_0009548 | N83 | — | 1 | — | — | — | 1 |
| Endometrioid carcinoma | D018269 | — | — | — | 1 | — | — | — | 1 |
| Adenocarcinoma | D000230 | — | — | — | 1 | — | — | — | 1 |
| Clear cell adenocarcinoma | D018262 | — | — | — | 1 | — | — | — | 1 |
Show 2 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Carcinoma | D002277 | — | C80.0 | 3 | — | — | — | — | 3 |
| Carcinosarcoma | D002296 | — | — | 1 | — | — | — | — | 1 |
| Hereditary breast and ovarian cancer syndrome | D061325 | — | — | 1 | — | — | — | — | 1 |
| Mullerian mixed tumor | D018200 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Mirvetuximab soravtansine |
| INN | mirvetuximab soravtansine |
| Description | Mirvetuximab soravtansine, sold under the brand name Elahere, is a medication used as a treatment for fallopian tube cancer or primary peritoneal cancer. Mirvetuximab soravtansine is a folate receptor alpha directed antibody and microtubule inhibitor conjugate.
|
| Classification | Antibody |
| Drug class | monoclonal antibodies; maytansinoid derivatives |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | 1453084-37-1 |
| RxCUI | — |
| ChEMBL ID | CHEMBL3545132 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB12489 |
| UNII ID | 98DE7VN88D (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Elahere – AbbVie
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 507 documents
View more details
Safety
Black-box Warning
Black-box warning for: Elahere
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
484 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use